FMP
23andMe Holding Co.
ME
NASDAQ
Inactive Equity
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
0.606 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Mr. Joseph Selsavage
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://www.23andme.comexchange
NASDAQ
Description
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas...
CIK
0001804591
ISIN
US90138Q3065
CUSIP
90138Q306
Address
349 Oyster Point Boulevard
Phone
650 938 6300
Country
US
Employee
560
IPO Date
Nov 23, 2020
Financial Statement
Earnings
ME Financial Summary
CIK
0001804591
Exchange
NASDAQ
Industry
Medical - Diagnostic...
Sector
Healthcare
CUSIP
90138Q306
ISIN
US90138Q3065
Country
US
Price
0.61
Beta
1.2
Volume Avg.
4.04M
Market Cap
13.34M
Shares
-
52-Week
0.48-12.76
DCF
-2.31
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.23andme.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ME News
Gordon Thompson
20 hours ago
SRx Health Solutions Inc.: A New Era in Health and Wellness
On April 30, 2025, Better Choice Company, Inc., known for its focus on health and wellness, underwent a significant transformation. The company, previously trading under the ticker BTTR, executed a stock split, exchanging 20 shares for every 27 shares held. This move coincided with a rebranding effort, as the company officially changed its name to SRx Health Solutions Inc. and began trading under the new ticker symbol ‘SRXH’ on the NYSE American stock market. The stock split and rebranding are ...
Alex Lavoie
a day ago
MetLife, Inc. (NYSE: MET) Financial Overview and Analyst Exp...
MetLife, Inc. (NYSE: MET) is a prominent player in the global financial services industry, offering a diverse range of products such as insurance, annuities, and asset management services. With operations spanning across the U.S., Asia, Latin America, Europe, the Middle East, and Africa, MetLife has established itself as a key provider in the financial sector since its founding in 1863. The consensus price target for MetLife's stock has experienced fluctuations over the past year. A year ago, t...
Andrew Wynn
a day ago
Methanex Corporation (NASDAQ:MEOH) Faces Analyst Downgrades ...
Methanex Corporation (NASDAQ:MEOH) is a leading global producer and supplier of methanol, a key component in various industrial and energy applications. The company operates across North America, the Asia Pacific, Europe, and South America, and manages a fleet of ocean-going vessels to support its extensive operations. Methanex competes with other chemical producers in the global market, striving to maintain its position as a top methanol supplier. Recently, the consensus price target for Metha...
Davit Kirakosyan
3 days ago
Loop Capital Slashes Meta Target on Ad Weakness Fears, Maint...
Loop Capital lowered its price target on Meta Platforms (NASDAQ:META) from $900 to $695 while maintaining a Buy rating, citing concerns about weakening ad pricing pressure ahead of the company’s first-quarter earnings report, scheduled to be released on Wednesday. The firm expects Meta to deliver solid Q1 results but warns that management may offer a softer second-quarter outlook. A key issue is the pullback by Chinese cross-border advertisers, who have been scaling back spending in the U.S. du...
Davit Kirakosyan
Apr 21, 2025
Scotiabank Slashes Meta’s Price Target Amid Ad Weakness and ...
Scotiabank reduced its price target on Meta Platforms (NASDAQ:META) to $525 from $627, while maintaining a Sector Perform rating, citing a convergence of headwinds weighing on the stock. Meta shares have fallen roughly 16% year-to-date as investors react to a combination of macro uncertainty, weakening digital ad trends, and the sharp pullback in ad spending from Chinese e-commerce players—most notably Temu, which had accounted for about 5-6% of Meta’s revenue. Data from app stores suggests a st...
Stuart Mooney
Apr 20, 2025
Medpace Holdings, Inc. (NASDAQ:MEDP) Analyst Sentiment and S...
Medpace Holdings, Inc. (NASDAQ:MEDP) is a company that offers comprehensive clinical research services for drug and medical device development. Operating across North America, Europe, and Asia, Medpace supports the pharmaceutical, biotechnology, and medical device industries. Their services cover the entire clinical development process, from Phase I to Phase IV, and include development plan design, project management, regulatory affairs, clinical monitoring, and data management. Over the past y...
Parth Sanghvi
Apr 16, 2025
Zuckerberg Considered Spinning Off Instagram Amid Antitrust ...
Meta Platforms CEO Mark Zuckerberg once seriously considered spinning off Instagram, citing rising antitrust risks—a move that has resurfaced in a high-stakes trial now underway in Washington, D.C. Trial Unveils Internal Concerns Over Antitrust Pressure During the second day of testimony in the U.S. Federal Trade Commission’s (FTC) bid to unwind Meta’s acquisitions of Instagram and WhatsApp, prosecutors introduced a 2018 internal memo authored by Zuckerberg. In it, the CEO floated the radi...
Davit Kirakosyan
Apr 15, 2025
MercadoLibre Viewed as a Top Emerging Markets Play at Benchm...
Benchmark initiated coverage on MercadoLibre (NASDAQ:MELI) with a Buy rating and a $2,500 price target, calling the Latin American e-commerce and fintech powerhouse a standout investment opportunity in the emerging markets space. According to Benchmark, MercadoLibre’s dominant market position—controlling roughly 25% of Latin America’s online retail sector—sets the stage for long-term expansion. Despite recent growth, e-commerce penetration in the region remains in the low teens, far below global...
